X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare IPCA Labs with Dishman Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs DISHMAN PHARMA - Comparison Results

IPCA LABS    Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS DISHMAN PHARMA IPCA LABS/
DISHMAN PHARMA
 
P/E (TTM) x 35.6 25.1 141.9% View Chart
P/BV x 3.4 3.3 101.0% View Chart
Dividend Yield % 0.2 0.7 22.9%  

Financials

 IPCA LABS   DISHMAN PHARMA
EQUITY SHARE DATA
    IPCA LABS
Mar-17
DISHMAN PHARMA
Mar-16
IPCA LABS/
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs643374 171.7%   
Low Rs503129 390.1%   
Sales per share (Unadj.) Rs254.4197.8 128.6%  
Earnings per share (Unadj.) Rs16.121.2 75.8%  
Cash flow per share (Unadj.) Rs29.834.7 85.8%  
Dividends per share (Unadj.) Rs1.002.00 50.0%  
Dividend yield (eoy) %0.20.8 22.0%  
Book value per share (Unadj.) Rs194.6179.9 108.1%  
Shares outstanding (eoy) m126.2080.69 156.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.31.3 177.0%   
Avg P/E ratio x35.711.9 300.4%  
P/CF ratio (eoy) x19.27.2 265.5%  
Price / Book Value ratio x2.91.4 210.5%  
Dividend payout %6.29.4 66.0%   
Avg Mkt Cap Rs m72,30020,306 356.1%   
No. of employees `00013.30.8 1,604.7%   
Total wages/salary Rs m6,9605,355 130.0%   
Avg. sales/employee Rs Th2,413.519,252.7 12.5%   
Avg. wages/employee Rs Th523.26,459.5 8.1%   
Avg. net profit/employee Rs Th152.42,064.1 7.4%   
INCOME DATA
Net Sales Rs m32,10615,961 201.2%  
Other income Rs m226265 85.0%   
Total revenues Rs m32,33216,226 199.3%   
Gross profit Rs m4,4484,103 108.4%  
Depreciation Rs m1,7301,091 158.6%   
Interest Rs m241944 25.5%   
Profit before tax Rs m2,7032,334 115.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m675624 108.3%   
Profit after tax Rs m2,0281,711 118.5%  
Gross profit margin %13.925.7 53.9%  
Effective tax rate %25.026.7 93.5%   
Net profit margin %6.310.7 58.9%  
BALANCE SHEET DATA
Current assets Rs m17,34011,018 157.4%   
Current liabilities Rs m9,5599,517 100.4%   
Net working cap to sales %24.29.4 257.7%  
Current ratio x1.81.2 156.7%  
Inventory Days Days100110 90.8%  
Debtors Days Days5735 163.2%  
Net fixed assets Rs m20,77916,304 127.4%   
Share capital Rs m252161 156.4%   
"Free" reserves Rs m24,49912,907 189.8%   
Net worth Rs m24,55314,516 169.1%   
Long term debt Rs m3,5174,189 84.0%   
Total assets Rs m39,59529,805 132.8%  
Interest coverage x12.23.5 352.2%   
Debt to equity ratio x0.10.3 49.6%  
Sales to assets ratio x0.80.5 151.4%   
Return on assets %5.78.9 64.3%  
Return on equity %8.311.8 70.1%  
Return on capital %10.517.5 59.8%  
Exports to sales %48.624.8 196.2%   
Imports to sales %14.23.7 381.1%   
Exports (fob) Rs m15,6173,956 394.8%   
Imports (cif) Rs m4,571596 766.6%   
Fx inflow Rs m15,6174,952 315.4%   
Fx outflow Rs m5,828697 836.4%   
Net fx Rs m9,7904,255 230.1%   
CASH FLOW
From Operations Rs m2,7642,786 99.2%  
From Investments Rs m-1,432-1,529 93.6%  
From Financial Activity Rs m-1,591-941 169.1%  
Net Cashflow Rs m-259316 -81.8%  

Share Holding

Indian Promoters % 45.9 61.4 74.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.4 3.7 308.1%  
FIIs % 25.3 12.7 199.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 22.1 78.7%  
Shareholders   36,892 46,261 79.7%  
Pledged promoter(s) holding % 2.1 35.8 6.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   PIRAMAL ENTERPRISES  NOVARTIS  DR. DATSONS LABS  MERCK LTD  GSK PHARMA  

Compare IPCA LABS With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day up 260 Points; Pharma Stocks Top Gainers(Closing)

After opening the day in red, share markets in India witnessed positive trading activity throughout the day and ended the day on a positive note.

Related Views on News

IPCA LABS Announces Quarterly Results (4QFY18); Net Profit Up 15.6%

May 30, 2018 | Updated on May 30, 2018

For the quarter ended March 2018, IPCA LABS has posted a net profit of Rs 513 m (up 15.6% YoY). Sales on the other hand came in at Rs 8 bn (up 17.6% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Jun 22, 2018 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS 8-QTR ANALYSIS

COMPARE IPCA LABS WITH

MARKET STATS